Moderna shares rose 14.21% on October 9, 2024, following a New York Times report that the NIH Foundation and National Cancer Institute will launch a $200 million, three-year therapeutic cancer vaccine initiative (TCVI) in December. The broker maps this to two China themes: tumor vaccines and mRNA T-cell engagers (TCEs), naming several domestic companies.
The broker is bullish on Chinese mRNA cancer vaccine and TCE developers, citing the upcoming NIH cancer vaccine program as a catalyst for the sector.
Free preview — more China A-share & HK research · About Us · Legal & Privacy